key: cord-0919553-xaowylib
authors: Muraoka, Daisuke; Situo, Deng; Shin-ichi, Sawada; Kazunari, Akiyoshi; Harada, Naozumi; Ikeda, Hiroaki
title: Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein
date: 2020-10-19
journal: Vaccine
DOI: 10.1016/j.vaccine.2020.10.039
sha: 6c98d26a76d6d438bd6c4d0cb8858a4b503f9aa3
doc_id: 919553
cord_uid: xaowylib

Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has been spreading throughout the world. To date, there are still no approved human vaccines for this disease. To develop an effective vaccine, the establishment of animal models for evaluating post-vaccination immune responses is necessary. In this study, we have identified a CTL epitope in the SARS-CoV-2 spike (S) protein that could be used to measure the cellular immune response against this protein. Potential predicted CTL epitopes of the SARS-CoV-2 S protein were investigated by immunizing BALB/c mice with a recombinant of the receptor-binding domain (RBD) of the S protein. Then, CD8(+) T cells specific for S-RBD were detected by stimulating with potential epitope peptides and then measuring the interferon-gamma production. Truncation of this peptide revealed that S-RBD-specific CD8(+) T cells recognized a D(d)-restricted S(526–533) peptide. In conclusion, this animal model is suitable for evaluating the immunogenicity of SARS-CoV-2 vaccines.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), was identified in China in late 2019 [1, 2] . As of July 19, 2020, more than 14 binds specifically and efficiently to angiotensin-converting enzyme 2 (ACE2) and thereby supports the entry of the virus into the host cell. It has been shown that neutralizing antibodies recognizing the RBD or other portions of the S protein block the binding of the protein to ACE2, thus preventing the infection of SARS-CoV-2 and other related coronaviruses [3] [4] [5] [6] . Therefore, many of the SARS-CoV-2 vaccines in development aim to induce S-RBD-or S protein-specific neutralizing antibodies by using the RBD or other parts of the S protein as an immunogen.

However, it was recently revealed that the durability of the humoral immune response to SARS-Cov2 is short [7] (unpublished data at https://doi.org/10.1101/2020.07.09.20148429). Furthermore, researchers have reported that plasma levels of the S1 protein-specific neutralizing antibody were under the detectable level in a number of patients who had recovered from COVID-19 (Wu et al. unpublished data at https://doi.org/10.1101/2020.03.30.20047365). T cells specific to SARS-CoV-2 epitopes have been detected in non-exposed healthy individuals [8] . Moreover, it has been reported that SARS-CoV-2-specific T-cell immune memory is induced in convalescent COVID-19 patients [9] . Furthermore, it has been demonstrated that the percentage of activated and proliferating virus-specific CD8 + T cells, such as spike-specific CD8 + T cells, is higher in mild patients, as compared to that in severe COVID-19 patients [10] . Furthermore, studies of SARS-CoV indicate that cellular immune responses induced by SARS-CoV infections have persisted for 11 years and that memory cytotoxic T lymphocytes (CTLs) contributed to protection from SARS-CoV re-challenge in mice [11, 12] . On the basis of these data, it is considered that the induction of a T-cell immune response against SARS-CoV-2 is important for protecting against COVID-19 development. Muraoka D et al., Page 4 These data also suggest that the capability of a SARS-CoV-2 vaccine to induce not only a humoral but also a cellular response should be taken into account in the development of vaccines and in their preclinical and clinical evaluations. Some animal models, including macaques and mice, were reported to be useful for the evaluation of the immunogenicity and/or efficacy of SARS-CoV-2 vaccines [6, 13, 14] . In particular, mouse models would be useful for the early research of vaccines.

However, methods to measure CD8 + CTL responses to specific SARS-CoV-2-derived antigens in mice have not been established. In particular, methods for evaluating the cellular immune responses against spike protein are essential because SARS-CoV-2 vaccines are being developed using this protein as an immunogen. In this study, we found that an epitope peptide (S 526-533 ) that is located at the C-terminus of S-RBD is recognized by CD8 + CTLs in BALB/c mice in a H2-D d -dependent manner. This is the first identification of a SARS-CoV-2-derived CTL epitope in mice that allows for the precise evaluation of the capability of candidate vaccines to induce a cellular immune response against S-RBD.

Female BALB/c mice were purchased from SLC Japan (Shizuoka, Japan) and used at 7-11 weeks of age. They were maintained at the Animal Center of Nagasaki University Graduate School of Medicine (Nagasaki, Japan). The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Nagasaki University Graduate School of Medicine. 

The S-RBD peptide of SARS-CoV-2 (amino acid residues (aa) 319-541) was purchased from RayBiotech (Peachtree Corners, GA, USA). Anti-H2-K d (SF1-1. 

The BALB/c mice were injected subcutaneously with 20 g of the S-RBD protein and 40 g of CpG ODN 1668 in 100 l PBS in the right flank at weekly intervals. with APC-conjugated anti-IFN- mAb. After washing, the cells were analyzed on the FACSCanto II system and the results analyzed with FlowJo software (TOMY Digital Biology, Tokyo, Japan).

Values are expressed as the mean ± standard deviation. Differences between groups were examined for statistical significance using the Student t-test. P values of <0.05 were considered statistically significant.

In this study, we attempted to identify minimal epitope(s) in the S-RBD of

was subcutaneously injected together with CpG ODN 1668 into naive BALB/c mice, twice weekly. At 1 week after the last immunization, the mice were sacrificed and their spleens removed. Specific CD8 + T-cell induction in the splenocytes was then analyzed by intracellular staining for IFN-γ after stimulation of the cells with short and long peptides in vitro. These peptides included potential S-RBD-derived epitopes that were predicted by the Immune Epitope Database (IEDB) analysis resource (http://www.iedb.org/) to bind to murine major histocompatibility complex (MHC) class I ( Table 2) . We prepared 10 peptides (peptide #1 to #10) that covered all predicted epitopes with a score of >0.15 and a percentile rank of <0.5 (Table 1 and In a study by Zhi et al. [15] , the SARS-CoV S peptide CYGVSATKL (aa 366-374) was recognized by CTLs in mice vaccinated with an adenoviral vector encoding the wild-type S protein of the virus. By contrast, a peptide of the homologous region on the SARS-CoV-2 S protein (CYGVSPTKL; aa 379-387) was not recognized by CTLs in our study. The replacement of residue A371 by K or D in this epitope of SARS-CoV led to decreased recognition of the peptide by CTLs, suggesting that residue A371 is critical for epitope recognition by CTLs [16] . To determine the minimal epitope(s) required, we synthesized five truncated peptides of peptide #10 (shown in Table 1 ) and used them to stimulate CTLs from the immunized mice in vitro. Although peptide #10-1 had an IEDB score of 0.0994 and a percentile rank of 0.97, all the short peptides tested were recognized at a similar degree by CTLs ( Fig.   2A ). We next tested lower concentrations of the short peptides, whereupon peptides #10-1 (S 526-533 , 8-mer) and #10-2 (S 525-533 , 9-mer) were found to be well recognized by CTLs in concentrations as low as 0.03 nM (Fig. 2B) . Because peptide #10-1 was shorter, it was considered the minimal epitope for CTLs. We then assessed the MHC restriction of this recognition using MHC blocking antibodies. The specific CD8 + T-cell response to peptide #10-1 was suppressed by the addition of the anti-H2-K d /D d mAb, but not the anti-H2-K d mAb (Fig. 2C) , indicating that this peptide was an H2-D d -restricted epitope. Taken together, the results indicated that we had succeeded in identifying an H2-D d -restricted S 526-533 peptide as an epitope for SARS-CoV-2 S-RBD-specific CD8 + T cells in mice.

In conclusion, we have established a BALB/c mouse model for the evaluation of CTL responses to the S-RBD of SARS-CoV-2. This model could be used to confirm 

NH is CEO and CTO of United Immunity, Co., Ltd. The other authors have no conflicts of interest related to this study to declare. Peptide S1 526-533 is identified as the H2-D d -restricted CD8 + CTL epitope.

(A, B) BALB/c mice were immunized with the S1 protein twice weekly. Splenocytes were obtained and specific T-cell induction was analyzed with intracellular cytokine staining assays, using stimulation with the indicated peptides. (B) The avidity of the induced S1-specific CD8 + T cells was analyzed with intracellular cytokine staining assays, using stimulation by graded doses of the peptides (ranging from 1 to 0.003 µM). (C) BALB/c mice were immunized with the S1 protein twice weekly.

Splenocytes were obtained and specific T-cell induction was stimulated with S1 526-533 peptides. MHC restriction of the induced S1-specific CD8 + T cells was analyzed with the intracellular cytokine staining assay after the addition of anti-H2-K d /D d or anti-H2-K d mAbs. These experiments were repeated two times with similar results.

Data are the mean ± SD. Muraoka D et al., Page 14 Declaration of interests ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

NH is CEO and CTO of United Immunity, Co., Ltd. The other authors have no conflicts of interest related to this study to declare.

A new coronavirus associated with human respiratory disease in China

A novel coronavirus from patients with pneumonia in China

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

Prospects for a MERS-CoV spike vaccine

Function, and antigenicity of the SARS-CoV-2 spike glycoprotein

A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals

T cells in COVID-19 -united in diversity

T cell responses to whole SARS coronavirus in humans

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein

Residue analysis of a CTL epitope of SARS-CoV spike protein by IFN-gamma production and bioinformatics prediction

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line

We thank YS for excellent technical assistance. This study was supported by Grants-in-Aid for Scientific Research (C) (DM). Muraoka D et al., Page 10